Merck says trial of combination treatment for colon cancer failed to meet main goal

Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of overall survival (OS) as a treatment for a type of colon cancer.

Previous post Buy Tesla’s stock ahead of these ‘significant’ positive catalysts, analyst says
Next post China stimulus plans spark a commodities rally, but a soft landing still isn’t a sure bet